Tempest Therapeutics Successfully Completes Direct Offering
Tempest Therapeutics, Inc. (NASDAQ: TPST), a pioneering clinical-stage biotechnology company, is making waves with its latest financial maneuver. The company has finalized a registered direct offering, with a striking $8.35 million deal on the table. This offering is aimed at bolstering their pipeline of innovative cancer treatment options, focusing on first-in-class targeted and immune-mediated therapeutics.
Details of the Offering
Under the terms of this direct offering, Tempest has mobilized the sale of 1,172,414 shares of common stock at a competitive market price of $3.625 per share. This offering is strategically positioned within regulations set forth by Nasdaq.
Alongside this, Tempest has engaged in a concurrent private placement, where it issued short-term unregistered warrants allowing for the purchase of an equivalent number of shares at an exercise price of $3.50. The excitement around these short-term unregistered warrants is palpable, as they are designed to be immediately exercisable and will expire 18 months after the effective date of the accompanying registration statement.
Financial Implications of the Offering
The gross proceeds from this direct offering are anticipated to be around $4.25 million prior to subtracting the costs associated with the placement agent and other expenses. If the additional potential gross proceeds from the warrants are realized, that figure could elevate to approximately $4.1 million. These funds are crucial for the company as they intend to channel them into working capital and general corporate purposes, ensuring that their innovative projects continue to thrive.
The Role of H.C. Wainwright & Co.
In this financial undertaking, H.C. Wainwright & Co. took on the role of exclusive placement agent, facilitating the smooth execution of this offering. Their expertise in navigating the complexities of financial markets proves invaluable, especially in the dynamic field of biotechnology.
Strategic Use of Funds
Tempest Therapeutics plans on using the proceeds primarily for operational impacts. The funding will support the ongoing development of their drug candidates, which utilize advanced mechanisms targeting tumors. This funding supports their overarching mission of creating innovative therapies for various cancers, enhancing their commitment to patient care.
About Tempest Therapeutics
Based in Brisbane, California, Tempest Therapeutics has a clear focus on developing therapeutics that harness both tumor-targeted mechanisms and immune responses to combat cancer effectively. Their diverse portfolio of small molecule product candidates has positioned them on the forefront of cancer treatment advancements.
Frequently Asked Questions
What is the purpose of the recent funding round?
The funding will primarily support Tempest Therapeutics' working capital and general corporate purposes, including ongoing drug development enhancements.
Who acted as the placement agent for this offering?
H.C. Wainwright & Co. was the exclusive placement agent for Tempest's registered direct offering.
What is the exercise price of the short-term unregistered warrants?
The short-term unregistered warrants are set at an exercise price of $3.50 per share.
What are the potential gross proceeds from the offering?
The offering could generate approximately $4.25 million initially, with a potential additional $4.1 million from the exercised warrants.
Where is Tempest Therapeutics headquartered?
Tempest Therapeutics is headquartered in Brisbane, California.
